The environment includes abiotic (nonliving) and biotic (living) factors. An ecosystem consists of all the biotic and abiotic factors in an area and their interactions
Answer:
Of the trillions of cells that compose our body, from neurons that relay signals throughout the brain to immune cells that help defend our bodies from constant external assault, almost every one contains the same 3 billion DNA base pairs that make up the human genome – the entirety of our genetic material. It is remarkable that each of the over 200 cell types in the body interprets this identical information very differently in order to perform the functions necessary to keep us alive. This demonstrates that we need to look beyond the sequence of DNA itself in order to understand how an organism and its cells function.
Explanation:
Answer:
Making an area unavailable to plants and animals
Explanation:
Answer: Antimicrobial proteins.
Explanation:
Antimicrobial proteins are the type of proteins produced by the keratinocytes on the body surfaces. These proteins acts as the barrier and kills the microorganism which is trying to enter the body.
These are larger proteins containing more than 100 amino acids. They are often lytic in nature.
The cell membrane of the microbes is disrupted by the action of these amino acids or proteins on them.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
